Literature DB >> 15685046

Complete response to adriamycin and ifosfamide in a patient with sarcomatoid renal cell carcinoma.

Mohammad H Rashid1, Cynthia T Welsh, Nabil K Bissada, Uzair B Chaudhary.   

Abstract

Sarcomatoid renal cell carcinoma (SRCC) is a heterogeneous disease with generally unreliable response to various therapies in clinical studies. We illustrate a case report in which a woman with metastatic SRCC had a complete and durable response to adriamycin and ifosfamide chemotherapy. We find this to be incongruous with expectations from some recently published data. It underscores the fact that the biology of SRCC needs to be studied in more detail for further subcataloging of the disease into diverse prognostic categories.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15685046     DOI: 10.1097/01.coc.0000139938.76332.6e

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  4 in total

1.  Temsirolimus in renal cell carcinoma with sarcomatoid differentiation: a report of three cases.

Authors:  Maria Carmen Areses; Urbano Anido Herranz; Beatriz Bernárdez Ferrán; Luis León Mateos; Jorge Garcia González; Rafael López López
Journal:  Med Oncol       Date:  2011-05-11       Impact factor: 3.064

2.  Phase 2 Trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid Renal-Cell Carcinoma.

Authors:  Abhishek Maiti; Maryam Nemati-Shafaee; Pavlos Msaouel; Lance C Pagliaro; Eric Jonasch; Nizar M Tannir; Amishi Y Shah
Journal:  Clin Genitourin Cancer       Date:  2017-08-10       Impact factor: 2.872

3.  [Sarcomatoid renal cell carcinoma. A rare and aggressive variation of primary renal cell carcinoma].

Authors:  A Bannowsky; I Leuschner; H Schiller; K Bothe; D Osmonov; K-P Jünemann; S Hautmann
Journal:  Urologe A       Date:  2007-04       Impact factor: 0.639

4.  Short-term effective treatment of CNS metastasis of sarcomatoid renal cell carcinoma with temozolomide and pegylated liposomal doxorubicin: A case report.

Authors:  Dagmar Beier; Gerhard Schuierer; Christoph P Beier; Ulrich Bogdahn
Journal:  Cases J       Date:  2008-10-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.